Several markers changed while others remained priorities. Read the individual results alongside the KDM-13 score to see the full five-month picture.
J.I.’s record covers January to June 2026, described in the source as five months. Triglycerides fell from 97 to 58 mg/dL, vitamin D rose from 36.0 to 49.4 ng/mL and total testosterone rose from 703 to 818 ng/dL. His KDM-13 score fell from 28.6 to 24.8 years.
Progress is easier to understand marker by marker
J.I.’s lower triglycerides and KDM-13 score sit beside broadly similar ApoB and higher homocysteine. That detail helps show why a follow-up review remains useful even when a headline score has improved.
Starting point and context
Not every change was large or favourable. hs-CRP remained close to its starting value, at 0.50 then 0.47 mg/L, and fasting insulin was 2.59 then 2.47 µIU/mL. LDL fell from 169 to 151 mg/dL, while ApoB was 102 then 104 mg/dL. These separate results are more informative than describing the whole profile as uniformly improved.
Explore EVA blood biomarker testing
The recorded results
| Biomarker | Jan 2026 | Jun 2026 |
|---|---|---|
| Triglycerides (mg/dL) | 97 | 58 |
| hs-CRP (mg/L) | 0.50 | 0.47 |
| Fasting Insulin (µIU/mL) | 2.59 | 2.47 |
| Vitamin D (ng/mL) | 36.0 | 49.4 |
| Total Testosterone (ng/dL) | 703 | 818 |
| LDL (mg/dL) | 169 | 151 |
| ApoB (mg/dL) | 102 | 104 |
| Homocysteine (µmol/L) | 9.74 | 11.0 |
| KDM-13 Biological Age | 28.6 yrs | 24.8 yrs |
Figures are reproduced from the case record, including qualitative entries and reported percentage changes. Source labels such as optimal describe the case’s interpretation, not a universal reference range. A dash indicates a value not supplied.
Context that matters
- J.I.’s chronological age is not supplied.
- The source describes the testosterone rise as occurring without pharmaceutical intervention or TRT. It does not establish a mortality benefit or prove adherence from the blood results alone.
- Homocysteine rose from 9.74 to 11.0 µmol/L; the source records an intensified protocol in response.
- The original planned a September panel after berberine and bergamot were active. No later result is included here, so the planned panel is not presented as a completed outcome.
The recorded protocol
The source does not supply a complete supplement list or dosing schedule for this case. The named interventions and relevant clinical context are described above and below.
Learn about personalised supplements
What remained in progress
ApoB and homocysteine remained priorities. Berberine and bergamot are named in the record, but a full supplement list and dosing schedule are not supplied. The case shows how follow-up can capture both progress and the areas that still need attention.
Reading the biological-age result
Biological-age scores are model outputs derived from the inputs available to that model. A lower score is not a measured gain in lifespan. Different models use different inputs and should be labelled and interpreted separately.
Does a lower KDM-13 score mean every blood marker improved?
No. J.I.’s score fell while ApoB stayed broadly similar and homocysteine rose. A biological-age score should be read alongside the individual markers and clinical context.
How this connects to EVA
EVA connects blood testing, clinician-reviewed personalised supplements and follow-up. Blood Intelligence uses your blood results; Elite DNA + Blood adds genetic information. DNA is optional. The aim is a personal plan grounded in your information, with review as new results become available.
Make your next result easier to interpret
If you already follow individual markers or biological-age scores, a clinician-reviewed plan can help connect those results to the questions that still need attention.
See how to start with EVAExplore blood testing, optional DNA and personalised supplements, with the current steps to get started in Dubai.
This is an individual observational case, not a controlled trial. Biomarker changes and biological-age scores do not establish the effect of a particular supplement, predict an individual’s lifespan or guarantee future results. The protocol described was personalised and is not a recommendation to self-prescribe. EVA supports informed health decisions and is not intended to diagnose, treat, cure or prevent disease. Consult a qualified healthcare provider for medical advice.
Source: EVA clinical case record supplied for publication. Observation dates and model names are shown in the case. Prepared for web publication in October 2026.